SCHEDULE 13G/A: PRIMECAP Management Discloses Significant 13.61% Stake in Pulmonx Corporation

PRIMECAP Management Co/CA/ has filed an amended Schedule 13G, revealing a beneficial ownership of 13.61% in Pulmonx Corporation, totaling 5,414,761 shares as of March 31, 2025.

Summary

• PRIMECAP MANAGEMENT CO/CA/ reported beneficial ownership of 5,414,761 shares of Pulmonx Corporation's common stock.
• This ownership represents 13.61% of the total class of securities.
• PRIMECAP MANAGEMENT CO/CA/ holds sole voting power over 5,009,561 shares.
• PRIMECAP MANAGEMENT CO/CA/ holds sole dispositive power over 5,414,761 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• PRIMECAP Odyssey Aggressive Growth Fund holds an interest of more than five percent of the total outstanding common stock of Pulmonx Corp.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the filing indicates a significant and passive institutional investment, which can be viewed as a vote of confidence in the company without implying activist intentions.

Positives

• The disclosure of a significant 13.61% stake by a reputable institutional investor like PRIMECAP Management Co/CA/ can be interpreted as a vote of confidence in Pulmonx Corporation's long-term prospects.
• A large institutional holding may provide stability to the stock and signal strong underlying fundamentals to other investors.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Pulmonx Corporation or PRIMECAP Management Co/CA/ regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Jorge A. Rodriguez, Deputy Chief Compliance Officer of PRIMECAP MANAGEMENT CO/CA/)

Industry Context

Pulmonx Corporation operates in the medical technology sector, specializing in minimally invasive treatments for lung diseases. The disclosure of a significant stake by PRIMECAP Management, a prominent investment adviser, reflects ongoing institutional interest in the healthcare and medical device industries, particularly in companies with innovative solutions.

Stakeholder Impact

• Shareholders may perceive the significant institutional investment by PRIMECAP Management as a positive indicator, potentially boosting investor confidence and market perception of Pulmonx Corporation's stock.

Key Dates

Keywords

Pulmonx Corporation, PRIMECAP Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Medical Devices, Healthcare, Stock Ownership, SEC Filing